Transgenic-based In Vivo Glycobiology Disease Model Development Service

Transgenic-based In Vivo Glycobiology Disease Model Development Service

Unlocking Insights: Transgenic Solutions for In Vivo Glycobiology Disease Models

At CD BioGlyco, our team of specialists has extensive expertise in the area of Developing Glycobiology Disease Models. We employ a range of Technologies to offer our clients thorough in vivo glycobiology disease model development services. The technologies we possess include gene editing, embryo implantation and cultivation, selective breeding, gene expression, and the transgenic method. The details of our transgenic-based in vivo glycobiology disease model development service are as follows.

  • Firstly, our experts engage in communication with you to identify the specific glycobiological disease under study, such as diabetes. Subsequently, they conduct an in-depth examination of the pathophysiology of the disease and the role played by glycosylated biomolecules. Based on the characteristics of the disease and the research objectives, an appropriate animal model such as mice, rats, or zebrafish that accurately replicates the features and progression of the human disease is selected.
  • Subsequently, we select appropriate genes or genomes based on the characteristics of the disease under study to mimic the disease progression and design transgenic constructs using transgenic technology.
  • Our experts then introduce the designed transgenic constructs into the embryos or stem cells of the target animals by microinjection, electroporation, or virus-mediated methods. The transgenic embryos or stem cells are then transplanted into the recipient mother to grow the transgenic animal, ensuring that the genetic stability and expression pattern of the transgenic animal are as expected.
  • Finally, we perform detailed phenotypic analyses of the transgenic animals, including physiology, pathology, and molecular biology, to assess whether the transgenic animals successfully mimic the characteristics of the disease under study.

Flowchart of developing in vivo disease models using transgenic-based glycobiology techniques. (CD BioGlyco)

Publication

Technology: Transgenic technology and gene knock out/knock in technology

Journal: Frontiers in oncology

IF: 4.848

Published: 2018

Results: This article focuses on transgenic mouse models used in cancer research. The article describes three methods for preparing transgenic mice: infection of mouse embryos by retroviruses, direct injection into the prokaryotic nucleus of fertilized mouse embryos by microinjection of DNA constructs or endonuclease-based reagents, and selective genetic manipulation of mouse embryonic stem cells by gene-targeted transgenic approaches. The article also mentions applications of the CRISPR/Cas9 system in cancer research, including the combination of classical transgenic models and CRISPR/Cas9 to generate transgenic mouse cancer models of germ cells or non-germ cells. The article also mentions some cancer models developed using transposon technology, such as colorectal cancer models and hepatocellular carcinoma models.

Fig.1 Explanation of how CRISPR/Cas9 modulates genes.Fig.1 Elucidation of the mechanism of how CRISPR/Cas9 influences gene expression. (Lampreht Tratar, et al., 2018)

Applications

  • Transgenic glycobiology disease models have been widely used to study human diseases, particularly to study the consequences of gene overexpression by overexpressing candidate genes associated with disease.
  • Transgenic glycobiology disease models have been used to study the mechanistic consequences of gene expression in the wrong cell or at the wrong time point, as well as studies that define embryonic cell fate.
  • The model can be used to evaluate the efficacy and safety of new drugs and accelerate the process of developing new drugs. By modelling the physiological and pathological processes of specific diseases, researchers can evaluate the effectiveness of drug candidates.

Advantages

  • Models constructed with transgenic technology offer greater control to precisely regulate the expression levels of disease-related genes or alter the structure of glycosylated biomolecules to better mimic the onset and progression of disease.
  • Transgenic technology allows researchers to construct many different animal models, including mice, rats, zebrafish, and more, thereby increasing the flexibility and diversity of research and contributing to a more comprehensive understanding of disease.
  • Utilizing transgenic technology to build glycobiological models has the potential to expedite the research process and enhance overall research productivity.

CD BioGlyco provides a full range of transgenic-based in vivo glycobiology disease model development services. Our team is committed to delivering dependable and top-notch support for your research in the glycobiology field. If you are interested in further details, please feel free to contact us.

Reference

  1. Lampreht Tratar, U.; et al. Transgenic mouse models in cancer research. Frontiers in oncology. 2018, 8: 268.
This service is for Research Use Only, not intended for any clinical use.

About Us

CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.

Contact Us

Copyright © CD BioGlyco. All rights reserved.
0